Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes

Phase 3

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Pioglitazone-Azilsartan

First Posted Date: 2010-05-17

Last Posted Date: 2012-05-21

Lead Sponsor: Takeda

Target Recruit Count: 26

Registration Number: NCT01124656

Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer

Phase 3

Completed

Conditions: Prostatic Neoplasms, Locally Advanced

Interventions: Drug: Leuprorelin SR
Radiation: Radiotherapy
Drug: Flutamide

First Posted Date: 2010-05-13

Last Posted Date: 2015-07-29

Lead Sponsor: Takeda

Target Recruit Count: 273

Registration Number: NCT01122121

Locations: 🇫🇷
Clinique Mutualiste, Saint-etienne, France

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

Phase 3

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: Febuxostat
Drug: Allopurinol

First Posted Date: 2010-04-09

Last Posted Date: 2018-06-14

Lead Sponsor: Takeda

Target Recruit Count: 6198

Registration Number: NCT01101035

Healthy and Renal Impairment Study of Colcrys (Colchicine, USP)

Phase 4

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Colchicine

First Posted Date: 2010-03-10

Last Posted Date: 2012-10-12

Lead Sponsor: Takeda

Target Recruit Count: 40

Registration Number: NCT01084278

Locations: 🇺🇸
West Coast Clinical Trials, Cypress, California, United States

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

Phase 2

Completed

Conditions: Renal Impairment

Interventions: Drug: Placebo
Drug: Febuxostat

First Posted Date: 2010-03-08

Last Posted Date: 2013-09-25

Lead Sponsor: Takeda

Target Recruit Count: 96

Registration Number: NCT01082640

Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout

Phase 2

Completed

Conditions: Joint Damage

Interventions: Drug: Placebo for Febuxostat
Drug: Febuxostat

First Posted Date: 2010-03-02

Last Posted Date: 2014-09-10

Lead Sponsor: Takeda

Target Recruit Count: 314

Registration Number: NCT01078389

A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults

Phase 1

Terminated

Conditions: Hypertension

Interventions: Drug: Azilsartan medoxomil (TAK-491)

First Posted Date: 2010-03-02

Last Posted Date: 2014-07-25

Lead Sponsor: Takeda

Target Recruit Count: 29

Registration Number: NCT01078376

Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones

Phase 2

Completed

Conditions: Hyperuricosuria
Kidney Stones

Interventions: Drug: Placebo
Drug: Febuxostat
Drug: Allopurinol

First Posted Date: 2010-03-01

Last Posted Date: 2013-02-15

Lead Sponsor: Takeda

Target Recruit Count: 99

Registration Number: NCT01077284

Instanyl® Non-Interventional Study

Completed

Conditions: Breakthrough Cancer Pain

First Posted Date: 2010-01-11

Last Posted Date: 2012-10-29

Lead Sponsor: Takeda

Target Recruit Count: 309

Registration Number: NCT01045603

Locations: 🇬🇧
Investigational site, Wiltshire, United Kingdom

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease

Phase 1

Completed

Conditions: Gastroesophageal Reflux

Interventions: Drug: Dexlansoprazole

First Posted Date: 2010-01-08

Last Posted Date: 2012-04-05

Lead Sponsor: Takeda

Target Recruit Count: 36

Registration Number: NCT01045096

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy